Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
2 minute read

Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist; Harmony Will Pay Bioprojet An Upfront License Fee Of $25.5M For The Exclusive Right

By Benzinga Newsdesk
April 11, 8:07 AM
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor

HRMY

Read More
1 minute read

Sight Sciences Announces The Publication Of Large-Scale, Real-World MIGS Study Demonstrating The Aqueous Outflow Restorative Procedure With OMNI Surgical System Technology Is Effective At Lowering Both IOP And IOP Reducing Medications At 2 Years In Pat…

By Benzinga Newsdesk
April 10, 4:08 PM
Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and

SGHT

Read More
2 minute read

Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies

By Vandana Singh
April 10, 3:23 PM
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections and strategic initiatives, Amphastar aims to capitalize on emerging opportunities in the endocrinology sector for continued growth.

AMPH

Read More
1 minute read

Blindness-Focused LENZ Therapeutics’ Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

By Vandana Singh
April 10, 3:19 PM
Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a bright future with a Buy rating and $34 price target.

ABBV